Thymosin Alpha-1 vs LL-37
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ta1, Zadaxin
A naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin Alpha-1 modulates T-cell function, enhances dendritic cell maturation, and promotes Th1 immune responses. It increases IL-2, interferon-alpha, and interferon-gamma production while reducing inflammatory cytokines. | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. |
| Common Dosing | 1.6 mg twice weekly 2-3x weekly | 100-200 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection or topical |
| Typical Duration | 6-12 months for hepatitis | Variable by protocol |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved internationally for chronic hepatitis B and C. Studies show improved outcomes when combined with chemotherapy for cancer. Research demonstrates benefits in sepsis, immunodeficiency, and vaccine response enhancement. | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. |
Frequently Asked Questions: Thymosin Alpha-1 vs LL-37
What is the difference between Thymosin Alpha-1 and LL-37?
Thymosin Alpha-1 is a immune peptide that a naturally occurring thymic peptide that enhances immune function. approved in over 35 countries for hepatitis b/c and as an immune adjuvant. LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Alpha-1 or LL-37?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while LL-37 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Alpha-1 and LL-37 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and LL-37 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.